Advertisement

HRT and the Secondary Prevention of Coronary Heart Disease

  • John C. Stevenson
Part of the Medical Science Symposia Series book series (MSSS, volume 11)

Abstract

In the past, the major indication for hormone replacement therapy (HRT) was the relief of acute menopausal symptoms, but more recently it is being used for the prevention and treatment of osteoporosis [1]. However, the major indication for its use in the future may be the prevention and treatment of cardiovascular disease.

Keywords

Postmenopausal Woman Hormone Replacement Therapy Estrogen Replacement Therapy Arterial Function Postmenopausal Estrogen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stevenson JC, Crook D, Godsland IF. Cardiovascular and skeletal effects of hormone replacement therapy. In: Seymour CA, Weetman AP, editors. Horizons in medicine No. 5. London: Blackwell Scientific Publications, 1994: 92–101.Google Scholar
  2. 2.
    Gordon T, Kannel WB, Hjortland MC, McNamara PM. Menopause and coronary heart disease. The Framingham Study. Ann Intern Med 1978;89:157–61.PubMedGoogle Scholar
  3. 3.
    Spencer CP, Cooper AJ, Stevenson JC. Clinical trials in progress with hormone replacement therapy. Exp Opin Invest Drugs 1996;5:739–49.CrossRefGoogle Scholar
  4. 4.
    Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990;97:1080–86.PubMedCrossRefGoogle Scholar
  5. 5.
    Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. N Eng J Med 1991;325:756–62.CrossRefGoogle Scholar
  6. 6.
    Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Finucane FF, Madans JII, Bush TL, et al. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med 1993;153:73–79.PubMedCrossRefGoogle Scholar
  8. 8.
    Falkeborn M, Persson I, Adami H-O, et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821–28.PubMedCrossRefGoogle Scholar
  9. 9.
    Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Gruchow HW, Anderson AJ, Barboriak JJ, et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988;115:954–63.PubMedCrossRefGoogle Scholar
  11. 11.
    Hong MK, Romm PA, Reagan K, Green CE, Rackley CE. Effects of estrogen replacement therapy on serum lipid values and angiographically defined coronary artery disease in postmenopausal women. Am J Cardiol 1992;69:176–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Sullivan JM, Zwang RV, Hughes JP, et al. Estrogen replacement therapy and coronary artery disease. Arch Intern Med 1990;150:2557–62.PubMedCrossRefGoogle Scholar
  13. 13.
    O’Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996;28:1111–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950–55.PubMedGoogle Scholar
  16. 16.
    Westerveld HT, Kock LAW, van Rijn JM, Erkelens DW, de Bruin TWA. 17 β-estradiol improves postprandial lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1995;80:249–53.PubMedCrossRefGoogle Scholar
  17. 17.
    Sack MN, Rader DJ, Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Godsland IF, Stevenson JC. Insulin resistance: Syndrome or tendency? Lancet 1995;346:100–3.PubMedCrossRefGoogle Scholar
  19. 19.
    Stevenson JC. The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 1995;49:87–90PubMedGoogle Scholar
  20. 20.
    Collins P, Rosano GMC, Sarrel PM, et al. 17 β-estradiol attentuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24–30.PubMedCrossRefGoogle Scholar
  21. 21.
    Jiang C, Poole-Wilson PA, Sarrel PM, et al. Effect of 17 β-oestradiol on contraction, Ca2+ current and intracellular free Ca2+ in guinea-pig isolated cardiac myocytes. Br J Pharmacol 1992;106:739–45.PubMedCrossRefGoogle Scholar
  22. 22.
    Proudler AJ, Ahmed AIH, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and scrum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995;346:89–90.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1997

Authors and Affiliations

  • John C. Stevenson

There are no affiliations available

Personalised recommendations